310 results on atopic dermatitis
Primary Objective* To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis Secondary Objectives* To explore skin and faecal microbiome in patients with seborrheic dermatitis * To evaluate the…
The current study has two main objectives:- To investigate if the effectiveness of CsA differs for NMF low vs. NMF normal (corresponding with FLG mutation vs. FLG wild type) in children with moderate-to-severe AD. - To investigate if the…
PrimaryThe primary objective of this study is to assess the safety and tolerability of BEN2293, administered as multiple topical doses to increasing body surface area (BSA), in patients with mild to moderate AD.SecondaryPharmacokinetics· To…
Primary:To provide access to abrocitinib to adolescent and adult patients with or without background topical therapy who have inadequate treatment options due to inadequate response or intolerance to available approved medicated topical and systemic…
Primary objective: To establish the PK profile after multiple SC administrations of tralokinumab in children with moderate-to-severe AD.Secondairy objectives: - To assess the safety and tolerability of multiple SC administrations of tralokinumab in…
Primary Objective Primary objective is to assess the efficacy of OM-85 versus matched placebo in children with moderate AD in reducing disease severity over the first 16 weeks and the first 24 weeks of the treatment period.Secondary Objectives…
Primary ObjectiveTo assess the efficacy of Gladskin Eczema Cream BID in patients with mild to moderate AD as assessed by EASI ScoreSecondary Objectives* To assess the pharmacodynamic effects of Gladskin Eczema Cream on the skin-microbiome, with…
To determine the relationship between phenotypic, genetic and biochemical features of AD. , Relevant bimarkers of the skin barrier function including the levels of NMFs, inflammatory mediators (e.g. IL-1 cytokines), SC lipids and serine proteases…
In the present project we would like to find out whether we can observe Treg into Th17 conversion in lesional skin and in the peripheral blood of patients with AD and compare the results to our findings in psoriatic patients and healthy controls.…
To evaluate efficacy of topical treatment with coal tar compared to topical treatment with corticosteroids in children aged 1 to <16 years with moderate to severe AD, based on the percentage change in Eczema Area and Severity Index (EASI) at…
As NB-UVB is known to be effective in AD, the excimer laser appears to be a promising treatment for localized AD. We designed a randomized single blind within-patient controlled trial to investigate the efficacy of the excimer laser versus routine…
Primary Objective- To assess efficacy and pharmacodynamic effects of topical omiganan BID Secondary Objectives- To assess safety and tolerability of topical omiganan BID
Gladskin cream will decrease the presence of Staphylococcus aureus and thereby will improve the clinical picture of the eczema patients.
Investigate the role of CD8+ T cells in AD by:a. Isolation of T cells from the skin and determination of the percentage and phenotype of CD8+ T cells in both acute and chronic AD, using the APT as an in vivo induction model. Comparison with…
to investigate whether the levels of a panel of biomarkers in dried blood spots can be used as a disease severity measurement tool in patients with AD, treated with topical steroids.
Primary objective• To explore the pharmacodynamic effects on a target lesion of topically applied omiganan in AD patientsSecondary Objectives• To assess safety and tolerability in AD patients• To evaluate the efficacy of omiganan compared to placebo…
Primary objective: To evaluate the efficacy of once daily doses of QAW039, as measured by EASI after 12 weeks of treatment, relative to placebo, in adult patients with moderate to severe AD. To evaluate safety and tolerability.Secondary objectives:…
To compare the MC with the UK working party diagnostic criteria (UKC) and clinical diagnosis and to refine the MC into a more convenient and reliable set of criteria.
This Phase 1, First in Human study is designed to assess the safety and systemic exposure (pharmacokinetics (PK)) of single dose (Part A,B) and multiple dose (thrice daily) for 14 days (Part C) topical M528101 Liquid 0.3% in healthy volunteers (Part…
The two main objectives are the identification of molecular and clinical signatures that can serve as diagnostic and/or severity-of-disease markers for AD in flare and remission. And the identification of key immunological and molecular pathways…